Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

Author： Fujisaka Yasuhito   Yamada Yasuhide   Yamamoto Noboru   Shimizu Toshio   Fujiwara Yutaka   Yamada Kazuhiko   Tamura Tomohide   Watanabe Hiroyuki   Sun Yu-Nien   Bass Michael   Seki Mitsuo  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.66, Iss.5, 2010-10, pp. : 935-943

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

By Doi Toshihiko   Ohtsu Atsushi   Fuse Nozomu   Yoshino Takayuki   Tahara Makoto   Shibayama Kazuhiro   Takubo Takatoshi   Weinreich David  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 227-235

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

By Dees E.   Infante Jeffrey   Cohen Roger   O’Neil Bert   Jones Suzanne   Mehren Margaret   Danaee Hadi   Lee Yih   Ecsedy Jeffrey   Manfredi Mark   Galvin Katherine   Stringer Bradley   Liu Hua   Eton Omar   Fingert Howard   Burris Howard  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 945-954

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

By Wakui Hiroshi   Yamamoto Noboru   Nakamichi Shinji   Tamura Yousuke   Nokihara Hiroshi   Yamada Yasuhide   Tamura Tomohide  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 511-516

Springer Publishing Company

Access to resources Recommend Favorite

Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma

By Azad Arun   Herbertson Rebecca   Pook David   White Shane   Mitchell Paul   Tebbutt Niall  

Acta Oncologica, Vol. 48, Iss. 4, 2009-05 ,pp. : 619-621

Informa Healthcare

Access to resources Recommend Favorite

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite